DE69922937D1 - Lactobacilli, die aggregations und mucin bindende gene als traeger von vakzinen enthalten - Google Patents

Lactobacilli, die aggregations und mucin bindende gene als traeger von vakzinen enthalten

Info

Publication number
DE69922937D1
DE69922937D1 DE69922937T DE69922937T DE69922937D1 DE 69922937 D1 DE69922937 D1 DE 69922937D1 DE 69922937 T DE69922937 T DE 69922937T DE 69922937 T DE69922937 T DE 69922937T DE 69922937 D1 DE69922937 D1 DE 69922937D1
Authority
DE
Germany
Prior art keywords
vaccines
genes
mucin
pathogenic
trailers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69922937T
Other languages
English (en)
Other versions
DE69922937T2 (de
Inventor
Ivan Casas
Hans Jonsson
Bo Mollstam
Stefan Roos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogaia Biologics AB
Original Assignee
Biogaia Biologics AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaia Biologics AB filed Critical Biogaia Biologics AB
Application granted granted Critical
Publication of DE69922937D1 publication Critical patent/DE69922937D1/de
Publication of DE69922937T2 publication Critical patent/DE69922937T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
DE69922937T 1998-03-16 1999-03-16 Lactobacilli, die aggregations und mucin bindende gene als traeger von vakzinen enthalten Expired - Fee Related DE69922937T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/039,773 US6100388A (en) 1998-03-16 1998-03-16 Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
US39773 1998-03-16
PCT/IB1999/000705 WO1999047657A2 (en) 1998-03-16 1999-03-16 Lactobacilli harboring aggregation and mucin binding genes as vaccine delivery vehicles

Publications (2)

Publication Number Publication Date
DE69922937D1 true DE69922937D1 (de) 2005-02-03
DE69922937T2 DE69922937T2 (de) 2005-12-29

Family

ID=21907276

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69922937T Expired - Fee Related DE69922937T2 (de) 1998-03-16 1999-03-16 Lactobacilli, die aggregations und mucin bindende gene als traeger von vakzinen enthalten

Country Status (8)

Country Link
US (1) US6100388A (de)
EP (1) EP1066375B1 (de)
AT (1) ATE286130T1 (de)
AU (1) AU767143B2 (de)
CA (1) CA2323634A1 (de)
DE (1) DE69922937T2 (de)
ES (1) ES2237094T3 (de)
WO (1) WO1999047657A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
US6100388A (en) * 1998-03-16 2000-08-08 Biogaia Biologies Ab Lactobacilli harboring aggregation gene as a vaccine delivery vehicle
FR2778187B1 (fr) * 1998-04-30 2001-06-22 Sanofi Elf Procede de selection de souches bacteriennes
US6146411A (en) * 1998-12-24 2000-11-14 Alsius Corporation Cooling system for indwelling heat exchange catheter
US7355092B2 (en) * 1999-12-27 2008-04-08 Ronald Marquardt Genetic vaccines for the production of chicken egg-yolk antibodies against enterotoxigenic Escherichia coli and other pathogens
MY128159A (en) * 2000-06-30 2007-01-31 Wyeth Corp Methods and composition for oral vaccination
JP2004514424A (ja) * 2000-09-25 2004-05-20 ソシエテ　デ　プロデユイ　ネツスル　ソシエテ　アノニム アレルギー反応を起こす個人の傾向を減少させることができる乳酸菌
US7060687B2 (en) * 2001-02-07 2006-06-13 Genmont Biotechnology Co. Live vaccines for allergy treatment
EP1381345B1 (de) * 2001-03-23 2008-07-09 Advanced Bionutrition Corporation Abgabe von mitteln zur krankheitskontrolle in aquakultur unter verwendung von bioaktive proteine enthaltender hefe
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
MY138219A (en) 2001-07-13 2009-05-29 Cms Peptides Patent Holding Company Ltd Biologically active peptides
US20040043003A1 (en) * 2002-01-31 2004-03-04 Wei Chen Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
US20050075298A1 (en) * 2002-01-31 2005-04-07 Wei Chen Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa
US7101565B2 (en) 2002-02-05 2006-09-05 Corpak Medsystems, Inc. Probiotic/prebiotic composition and delivery method
CA2506031A1 (en) * 2002-11-15 2004-06-03 Vib Vzw Self-containing lactobacillus strain comprising a thya mutation and therapeutic applications thereof
US7517681B2 (en) * 2003-01-29 2009-04-14 Biogaia Ab Selection and use of lactic acid bacteria for reducing dental caries and bacteria causing dental caries
US6872565B2 (en) 2003-01-29 2005-03-29 Biogaia Ab Product containing Lactobacillus reuteri strain ATTC PTA-4965 or PTA-4964 for inhibiting bacteria causing dental caries
US20050281756A1 (en) * 2004-06-14 2005-12-22 Eamonn Connolly Use of lactic acid bacteria for decreasing gum bleeding and reducing oral inflammation
WO2004069156A2 (en) * 2003-01-30 2004-08-19 The Regents Of The University Of California Inactivated probiotic bacteria and methods of use thereof
US20050220777A1 (en) * 2003-11-21 2005-10-06 Stefan Roos Selection of lactic acid bacteria enhancing the immune response against Streptococcus pneumoniae
TWI353252B (en) 2004-04-28 2011-12-01 Cms Peptides Patent Holding Company Ltd Biologically active peptide vapeehptllteaplnpk der
US20100233312A9 (en) * 2005-04-11 2010-09-16 The Procter & Gamble Company Compositions comprising probiotic and sweetener components
EP1723965A1 (de) 2005-05-18 2006-11-22 Stallergenes Sa Zusammensetzungen zur Einleitung antigenspezifischer immunologischer Toleranz durch orale Immunisierung
NZ591825A (en) 2005-07-26 2012-10-26 Cms Peptides Patent Holding Company Ltd Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating fatigue
JP5410759B2 (ja) 2005-11-29 2014-02-05 アクトジェニックス・エヌブイ 抗原に対する粘膜寛容の誘導
US8734823B2 (en) * 2005-12-14 2014-05-27 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8278094B2 (en) 2005-12-14 2012-10-02 The Invention Science Fund I, Llc Bone semi-permeable device
US20110183351A1 (en) * 2010-01-22 2011-07-28 Hyde Roderick A Compositions and methods for therapeutic delivery with microorganisms
US20110172826A1 (en) * 2005-12-14 2011-07-14 Amodei Dario G Device including altered microorganisms, and methods and systems of use
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US20080260898A1 (en) * 2006-03-17 2008-10-23 Marko Stojanovic Compositions comprising probiotic and sweetener components
US7374924B2 (en) * 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic
US8603460B2 (en) * 2006-06-05 2013-12-10 Brogaia AB Method of making a Lactobacillus reuteri with increased acid tolerance
EP2774621B1 (de) 2007-01-25 2018-01-24 Intrexon Actobiotics NV Behandlung von Immunerkrankungen durch mukosale Abgabe von Antigenen
US7910127B2 (en) * 2007-03-02 2011-03-22 Biogaia Ab Use of lactic acid bacteria for improving food lysine absorption of pet animals
EP2164512A2 (de) * 2007-06-20 2010-03-24 Actogenix N.V. Verfahren und zusammensetzungen zur behandlung von mucositis
CN103403026B (zh) 2009-09-25 2016-05-11 美国政府(由卫生和人类服务部的部长所代表) Hiv-1中和抗体及其用途
US9695230B2 (en) 2011-12-08 2017-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein
US9452205B2 (en) * 2012-09-24 2016-09-27 Montana State University Recombinant Lactococcus lactis expressing Escherichia coli colonization factor antigen I (CFA/I) fimbriae and their methods of use
WO2014126921A1 (en) 2013-02-12 2014-08-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that neutralize norovirus
EP2994163B1 (de) 2013-05-09 2019-08-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Single-domain-vhh-antikörper gegen norovirus gi.1 und gii.4 und deren verwendung
WO2015145250A2 (en) 2014-03-27 2015-10-01 Ghosh Sambuddha Expression of a single chain antibody against salmonella in lactobacillus
US10072070B2 (en) 2014-12-05 2018-09-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Potent anti-influenza A neuraminidase subtype N1 antibody
RU2021135949A (ru) 2016-09-13 2022-04-14 Интрексон Актобиотикс Н.В. Мукоадгезивный микроорганизм
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
CN107961373A (zh) * 2017-11-14 2018-04-27 东北农业大学 一种用于预防猪流行性腹泻的基因工程亚单位口服疫苗株及其构建方法和用途
EP3921424A1 (de) * 2019-02-05 2021-12-15 Elanco Us Inc. Genetisch modifizierter lactobacillus und dessen verwendungen
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
WO2023078279A1 (zh) * 2021-11-04 2023-05-11 澄交生物科技股份有限公司 免疫原性组合物及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851794A (en) * 1990-10-22 1998-12-22 Alfa Laval Ab Collagen binding protein as well as its preparation
SE9302856D0 (sv) * 1993-09-06 1993-09-06 Martin Lindberg Method and means for producing a plasmapeotein-binding protein
AU2149495A (en) * 1995-04-11 1996-10-30 Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno Method for the construction of vectors for lactic acid bacte ria like lactobacillus such that the bacteria can efficientl y express, secrete and display proteins at the surface
US5534253A (en) * 1995-06-07 1996-07-09 Biogaia Ab Method of treating enteropathogenic bacterial infections in poultry
GB9518323D0 (en) * 1995-09-07 1995-11-08 Steidler Lothar Materials and methods relating to the attachment and display of substances on cell surfaces
US5837238A (en) * 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
US6100388A (en) * 1998-03-16 2000-08-08 Biogaia Biologies Ab Lactobacilli harboring aggregation gene as a vaccine delivery vehicle

Also Published As

Publication number Publication date
AU3049699A (en) 1999-10-11
ES2237094T3 (es) 2005-07-16
US6100388A (en) 2000-08-08
CA2323634A1 (en) 1999-09-23
WO1999047657A2 (en) 1999-09-23
DE69922937T2 (de) 2005-12-29
ATE286130T1 (de) 2005-01-15
EP1066375B1 (de) 2004-12-29
EP1066375A2 (de) 2001-01-10
AU767143B2 (en) 2003-10-30
WO1999047657A3 (en) 1999-12-09

Similar Documents

Publication Publication Date Title
DE69922937D1 (de) Lactobacilli, die aggregations und mucin bindende gene als traeger von vakzinen enthalten
Hidalgo-Cantabrana et al. CRISPR-based engineering of next-generation lactic acid bacteria
Valdez et al. First Litopenaeus vannamei WSSV 100% oral vaccination protection using CotC:: Vp26 fusion protein displayed on Bacillus subtilis spores surface
Kandasamy et al. Lactobacilli and Bifidobacteria enhance mucosal B cell responses and differentially modulate systemic antibody responses to an oral human rotavirus vaccine in a neonatal gnotobiotic pig disease model
US20180305777A1 (en) Phage insensitive streptococcus thermophilus
DE69806408T2 (de) Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten
US7951575B2 (en) Isolated phages and their use in food or pet food products
Wang et al. Identification of a surface protein from Lactobacillus reuteri JCM1081 that adheres to porcine gastric mucin and human enterocyte-like HT-29 cells
Ricca et al. Mucosal vaccine delivery by non-recombinant spores of Bacillus subtilis
Guo et al. A novel rapid and continuous procedure for large-scale purification of magnetosomes from Magnetospirillum gryphiswaldense
Azizpour et al. Lactococcus lactis: A new strategy for vaccination
CN104560896B (zh) 一种在大肠杆菌中表达ms2假病毒颗粒的方法
CA2469894A1 (en) Use of micro-organisms for a directed delivery of substances to specific parts of the gut
JP2018505666A5 (de)
Castillo‐Romero et al. Production and purification of bacterial membrane vesicles for biotechnology applications: Challenges and opportunities
Kwon et al. Generation of Vibrio anguillarum ghost by coexpression of PhiX 174 lysis E gene and staphylococcal nuclease A gene
Kim et al. Live attenuated Salmonella enterica serovar Typhimurium expressing swine interferon-α has antiviral activity and alleviates clinical signs induced by infection with transmissible gastroenteritis virus in piglets
RU2441907C1 (ru) Способ приготовления лечебно-профилактического препарата из живых штаммов микроорганизмов лакто- и бифидобактерий "lb-комплекс л"
WO2019160116A1 (ja) バチルス属細菌、インターロイキン－２２産生誘導剤、皮膚バリア機能増強剤
Ibrahim et al. Effect of temperature on in vitro adhesion of potential fish probiotics
Shonyela et al. Recombinant Lactobacillus plantarum NC8 strain expressing porcine rotavirus VP7 induces specific antibodies in BALB/c mice
Zhang et al. Auxotrophic Lactobacillus Expressing Porcine Rotavirus VP4 Constructed Using CRISPR-Cas9D10A System Induces Effective Immunity in Mice
CN103421731A (zh) 一种副猪嗜血杆菌减毒沙门氏菌苗
JPS63233929A (ja) 抗原性細菌溶解質、その製造方法およびそれを含有する薬剤組成物
Rosales-Mendoza et al. Nanovaccines and the History of Vaccinology

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee